Press Releases :: Nighthawk Biosciences, Inc. (SCPX)

Mar 05, 2020 4:45pm EST

Heat Biologics, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City

Mar 05, 2020 9:00am EST

Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Mar 04, 2020 3:10pm EST

Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Company’s Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19

Mar 03, 2020 8:00am EST

Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Jan 21, 2020 4:05pm EST

Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

Jan 16, 2020 9:50am EST

Heat Biologics, Inc. Prices $7,000,000 Public Offering

Dec 16, 2019 7:00am EST

Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130

Nov 20, 2019 8:00am EST

Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Nov 18, 2019 8:00am EST

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

Nov 15, 2019 8:30am EST

Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

rss_feed News RSS